SCHEMBL2520258

SCHEMBL2520258

Fc1ccc(-c2cc3n(n2)CCC3)cc1

nearest known ligand 0.65

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
THRB P10828 4/20 0.43
TGFBR1 P36897 3/20 0.41
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2523357 0.95 KDM4E (0.41) KDM4ELMNAMAPTALOX15TSHR
SCHEMBL2524849 0.94 KDM4E (0.42) KDM4ELMNAMAPTALOX15TSHR
SCHEMBL14844863 0.84 THRB (0.45) THRBTGFBR1KDM4E
SCHEMBL2525007 0.83 THRB (0.43) THRBTGFBR1KDM4ELMNAMAPT
SCHEMBL2522518 0.83 GRM5 (0.51)
SCHEMBL25227540 0.80 TSHR (0.43) THRBTGFBR1KDM4ELMNAMAPT
SCHEMBL29831821 0.80 GRM5 (0.53)
SCHEMBL29050018 0.80 GRM5 (0.53)
SCHEMBL2532469 0.80 WDR5 (0.50) THRBTGFBR1KDM4ELMNAMAPT
SCHEMBL16708791 0.78 CYP1A2 (0.44) THRBTGFBR1KDM4ELMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192699-A1 COMPOUNDS AS CASEIN KINASE INHIBITORS Gritscience Biopharmaceuticals Co., Ltd. (CN) 2023-06-22 US disclosed
EP-4126878-A1 COMPOUNDS AS CASEIN KINASE INHIBITORS Gritscience Biopharmaceuticals Co., Ltd. (CN) 2023-02-08 EP disclosed
CN-115335057-A Method for inhibiting casein kinase 北京原基华毅生物科技有限公司 2022-11-11 CN disclosed
CN-115298183-A Compounds as casein kinase inhibitors 北京原基华毅生物科技有限公司 2022-11-04 CN disclosed
US-9956220-B2 Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2018-05-01 US disclosed
US-9956220-B2 Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2018-05-01 US disclosed
US-9956220-B2 Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2018-05-01 US disclosed
US-20170137427-A1 IMIDAZO-PYRIDAZINE DERIVATIVES AS CASEIN KINASE 1 DELTA/EPSILON INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2017-05-18 US disclosed
US-20170137427-A1 IMIDAZO-PYRIDAZINE DERIVATIVES AS CASEIN KINASE 1 DELTA/EPSILON INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2017-05-18 US disclosed
US-20170137427-A1 IMIDAZO-PYRIDAZINE DERIVATIVES AS CASEIN KINASE 1 DELTA/EPSILON INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2017-05-18 US disclosed
US-20140364456-A1 HETEROCYCLYLPYRI(MI)DINYLPYRAZOLE BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-12-11 US disclosed
EP-2763993-A1 HETEROCYCLYLPYRI(MI)DINYLPYRAZOLE Bayer Intellectual Property GmbH (DE) 2014-08-13 EP disclosed
CN-103958518-A Heterocyclylpyri(mi)dinylpyrazole BAYER IP GMBH 2014-07-30 CN disclosed
EP-2556073-B1 BICYCLIC PYRIDINYL PYRAZOLES BAYER IP GMBH (DE) 2014-07-23 EP disclosed
US-8507472-B2 Bicyclic pyridinylpyrazoles BAYER CROPSCIENCE AG (DE) 2013-08-13 US disclosed
WO-2013050434-A1 HETEROCYCLYLPYRI(MI)DINYLPYRAZOLE BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-04-11 WO disclosed
CN-102947303-A Bicyclic pyrimidinyl pyrazoles BAYER CROPSCIENCE AG 2013-02-27 CN disclosed
EP-2556073-A1 BICYCLIC PYRIMIDINYL PYRAZOLES Bayer Intellectual Property GmbH (DE) 2013-02-13 EP disclosed
WO-2011124539-A1 BICYCLIC PYRIMIDINYL PYRAZOLES BAYER CROPSCIENCE AG (DE) 2011-10-13 WO disclosed
US-20110251178-A1 Bicyclic Pyridinylpyrazoles BAYER CROPSCIENCE AG (DE) 2011-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251178-A1 Bicyclic Pyridinylpyrazoles PLPBP, PNPO, PIR THRB 3803/4885TGFBR1 2921/4885KDM4E 2248/4885
US-20230192699-A1 COMPOUNDS AS CASEIN KINASE INHIBITORS CSNK2A3, CSNK1A1, CSNK1G3 THRB 2602/4885TGFBR1 3541/4885KDM4E 836/4885
US-20170137427-A1 IMIDAZO-PYRIDAZINE DERIVATIVES AS CASEIN KINASE 1 DELTA/EPSILON INHIBITORS CSNK1A1, CSNK1G1, CSNK1E THRB 1548/4885TGFBR1 1795/4885KDM4E 1468/4885
US-20140364456-A1 HETEROCYCLYLPYRI(MI)DINYLPYRAZOLE H1-0, NQO2, CCNI THRB 4167/4885TGFBR1 1833/4885KDM4E 2973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.